+++
title = "Pfizer COVID vaccine price hike to boost revenue for years, rivals may follow"
description = "Pfizer's plan to as much as quadruple U.S. prices for its COVID-19 vaccine next year is beyond Wall Street's expectations and will spur its revenue for years despite weaker than anticipated demand for the new booster shot so far, analysts said."
date = "2022-10-22 05:48:27"
slug = "6353840d693f6ed9a8505d55"
image = "https://i.imgur.com/nnQtzd3.jpg"
score = "2290"
categories = ['covid', 'boost', 'states']
+++

Pfizer's plan to as much as quadruple U.S. prices for its COVID-19 vaccine next year is beyond Wall Street's expectations and will spur its revenue for years despite weaker than anticipated demand for the new booster shot so far, analysts said.

## Highlights

- Pfizer's plan to as much as quadruple U.S.
- prices for its COVID-19 vaccine next year is beyond Wall Street's expectations and will spur its revenue for years despite weaker than anticipated demand for the new booster shot so far.
- Pfizer said on Thursday evening that it is targeting a range of $110 to $130 a dose for the vaccine once the United States moves to a commercial market next year.
- Wall Street was expecting price hikes to enable manufacturers to meet revenue forecasts for 2023 and beyond.
- The price range announced by Pfizer represented a more than 10,000% markup over what experts have estimated it costs the vaccine makers to produce the shots.

---

{{< rawhtml >}}
  <p class="article-category">
    <a target="_blank" href="https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-covid-vaccine-price-hike-seen-giving-revenue-boost-years-2022-10-21/">READ THE ORIGINAL ARTICLE</a>
  </p>
{{< /rawhtml >}}
